| |
MTHFRC677T MTHFRA1298C |
| CC |
CT |
TT |
P for interaction |
AA |
AC |
CC |
P for interaction |
|
Colorectal cancer (n=70) |
|
|
|
|
|
|
|
|
| Surgery |
|
|
|
|
|
|
|
|
| No |
0(0%) |
5(83.3%) |
1(16.7%) |
|
4(100%) |
0(0%) |
0(0%) |
|
| Palliative |
11(36.7%) |
16(53.3%) |
3(10%) |
0.28 |
17(65.4%) |
7(26.9%) |
2(7.7%) |
0.58 |
| Radical |
16(47.1%) |
16(47.1%) |
2(5.9%) |
|
19(57.6%) |
11(33.3%) |
3(9.1%) |
|
| Neoadjuvant chemotherapy |
|
|
|
|
|
|
|
|
| No |
21(42%) |
26(52%) |
3(6%) |
0.35* |
26(59.1%) |
14(31.8%) |
4(9.1%) |
0.26* |
| Yes |
6(30%) |
11(55%) |
3(15%) |
|
14(73.7%) |
4(21.1%) |
1(5.3%) |
|
| Kind of chemotherapy |
|
|
|
|
|
|
|
|
| Xeloda |
5(83.3%) |
7(63.6%) |
3(100%) |
|
11(78.6%) |
2(50%) |
1(100%) |
|
| Folfiri |
0(0%) |
1(9.1%) |
0(0%) |
0.69 |
0(0%) |
1(25%) |
0(0%) |
0.35 |
| Folfox |
1(16.7%) |
3(27.3%) |
0(0%) |
|
3(21.4%) |
1(25%) |
0(0%) |
|
| LV5-FU2
Adjuvant chemotherapy |
|
|
|
|
|
|
|
|
| No |
5(31.3%) |
8(50%) |
3(18.8%) |
0.49* |
8(61.5%) |
5(38.5%) |
0(0%) |
|
| Yes |
22(40.7%) |
29(53.7%) |
3(5.6%) |
|
32(64%) |
13(26%) |
5(10%) |
0.86* |
| Kind of chemotherapy |
|
|
|
|
|
|
|
|
| Xeloda |
0(0%) |
2(6.9%) |
0(0%) |
|
0(0%) |
2(15.4%) |
1(20%) |
|
| Folfiri |
3(13.6%) |
0(0%) |
0(0%) |
0.29 |
3(9.4%) |
0(0%) |
0(0%) |
0.17 |
| Folfox |
17(77.3%) |
22(75.9%) |
3(100%) |
|
25(78.1%) |
8(61.5%) |
4(80%) |
|
| LV5-FU2 |
2(9.1%) |
5(17.2%) |
0(0%) |
|
4(12.5%) |
3(23.1%) |
0(0%) |
|
P was calculated between CC versus CT+TT genotype for MTHFRC677T, For MTHFR A1298C P was calculated between AA versus AC+CC genotype |
